

해외 바이오의약품 임상 현황 (2019.08.27~2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

○ 미국 67건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04063215	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy	Traumatic Brain Injury	Drug: HB-adMSC	Hope Biosciences The University of Texas Health Science Center, Houston	Phase 1 Phase 2
NCT04047732	Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	TGM-1 Related Autosomal Recessive Congenital Ichthyosis	Biological: KB105	Krystal Biotech, Inc.	Phase 1 Phase 2
NCT04039230	Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.	Breast Cancer	Drug: Talazoparib Drug: Sacituzumab Govitecan	Massachusetts General Hospital Pfizer	Phase 1 Phase 2
NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	Advanced Malignant Solid Neoplasm Metastatic Carcinoma in the Liver Metastatic Carcinoma in the Lung Metastatic Malignant Neoplasm in the Thoracic Cavity Metastatic Malignant Solid Neoplasm	Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156 Biological: Ipilimumab Biological: Nivolumab Radiation: Stereotactic Body Radiation Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04018755	Open-label Study of Anakinra in MPS III	Mucopolysaccharidosis III	Biological: anakinra	Los Angeles Biomedical Research Institute Cure Sanfilippo Foundation Sobi	Phase 2 Phase 3
NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	Melanoma	Biological: hu14.18-IL2 Radiation: Radiation Therapy Biological: Nivolumab Biological: Ipilimumab	University of Wisconsin, Madison National Cancer Institute (NCI) Bristol-Myers Squibb Apeiron Biologics Provenance Biopharmaceuticals	Phase 1 Phase 2
NCT03532295	Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas	Glioma Glioblastoma	Drug: Epacadostat Drug: Avelumab Drug: Bevacizumab Radiation: Radiation therapy Procedure: Peripheral blood draw	Washington University School of Medicine Incyte Corporation	Phase 1 Phase 2
NCT04044430	Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer	Metastatic Colon Adenocarcinoma Metastatic Colorectal Adenocarcinoma Metastatic Microsatellite Stable Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer Stage III Colorectal Cancer Stage III Rectal Cancer Stage IIIA Colon Cancer Stage IIIA Colorectal Cancer Stage IIIA Rectal Cancer Stage IIIB Colon Cancer Stage IIIB Colorectal Cancer Stage IIIB Rectal Cancer Stage IIIC Colon Cancer Stage IIIC Colorectal Cancer Stage IIIC Rectal Cancer Stage IV Colon Cancer Stage IV Colorectal Cancer Stage IV Rectal Cancer Stage IVA Colon Cancer Stage IVA Colorectal Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Colorectal Cancer Stage IVB Rectal Cancer Stage IVC Colon Cancer Stage IVC Colorectal Cancer Stage IVC Rectal Cancer	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab Other: Questionnaire Administration	University of California, San Francisco Array BioPharma Bristol-Myers Squibb (BMS)	Phase 1 Phase 2
NCT03985423	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH	Hemophagocytic Lymphohistiocytoses	Drug: Emapalumab-Lzsg	NovImmune SA	Phase 2 Phase 3
NCT04068753	Niraparib in Combination With TSR-042 in Patients With Recurrent or Progressive Cervix Cancer	Recurrent Cervix Cancer Progressive Cervix Cancer	Drug: Niraparib Drug: TSR-042	University of Oklahoma Tesaro, Inc.	Phase 2
NCT04067726	RANKL Inhibition and Mammographic Breast Density	Dense Breasts	Drug: Denosumab Drug: Placebo Drug: Calcium Drug: Vitamin D3 Procedure: Core needle biopsy Procedure: Blood draw	Washington University School of Medicine National Institutes of Health (NIH)	Phase 2
NCT04061980	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	BRAF NP_004324.2:p.V600M BRAF V600E Mutation Present Metastatic Thyroid Gland Carcinoma Refractory Thyroid Gland Carcinoma Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab	OHSU Knight Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04061746	Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells	Diabetes Mellitus, Type 1	Biological: Mesenchymal Stem Cells (MSCs) Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)	Medical University of South Carolina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1
NCT04047810	Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Biological: Mesenchymal Stem Cells	Mayo Clinic	Phase 1
NCT04047706	Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	Glioblastoma	Biological: IDO1 Inhibitor BMS-986205 Biological: Nivolumab Radiation: Radiation Therapy Drug: Temozolomide	Northwestern University National Cancer Institute (NCI)	Phase 1
NCT04032964	Dose Finding Study of L19TNF and Doxorubicin in Patients With STS	Soft Tissue Sarcoma	Drug: L19TNF Drug: DOXORUBICIN	Philogen S.p.A.	Phase 1
NCT04030052	Emicizumab PUPs and Nuwiq ITI Study	Hemophilia A	Drug: Nuwiq (low dose protocol) Drug: Emicizumab Drug: Nuwiq (Atlanta protocol)	Emory University	Phase 3
NCT04024878	NeoVax With Nivolumab in Patients With Ovarian Cancer	Ovarian Cancer	Drug: Nivolumab Biological: NeoVax Procedure: Core Needle Biopsy	Dana-Farber Cancer Institute United States Department of Defense	Phase 1
NCT04024761	A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Haploidentical Hematopoietic Cell Transplantation	Leukemia	Biological: CIML NK Drug: Fludarabine Drug: Cyclophosphamide	Dana-Farber Cancer Institute Dunkin Donuts	Phase 1
NCT04020575	Phase I Study of Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)	Metastatic Breast Cancer	Biological: huMNC2-CAR44 CAR T cells Biological: huMNC2-CAR44 CAR T cells @ RP2D	Minerva Biotechnologies Corporation Fred Hutchinson Cancer Research Center	Phase 1

해외 바이오의약품 임상 현황 (2019.08.27~2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

NCT04003246	Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer Lung Cancer Stage III	Radiation: Thoracic RT and Durvalumab Drug: Consolidative Durvalumab	University of Texas Southwestern Medical Center AstraZeneca	Phase 3
NCT04003207	Growth Hormone Treatment in Children With Phelan McDermid Syndrome	Phelan McDermid Syndrome	Drug: Recombinant human Growth hormone	Swathi Sethuram Icahn School of Medicine at Mount Sinai	Phase 2
NCT03999424	Autologous Human Schwann Cells in Peripheral Nerve Repair	Peripheral Nerve Injuries	Biological: autologous human Schwann cells	W. Dalton Dietrich The Miami Project to Cure Paralysis University of Miami	Phase 1
NCT03991884	Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia	Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Recurrent B Acute Lymphoblastic Leukemia Recurrent B Lymphoblastic Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory B Lymphoblastic Lymphoma	Drug: Etoposide Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Vincristine Drug: Vincristine Sulfate Drug: Prednisone Drug: Cyclophosphamide Biological: Inotuzumab Ozogamicin Biological: Rituximab	University of Washington National Cancer Institute (NCI)	Phase 1
NCT03981952	Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine	Risk Reduction	Biological: Trivalent Invasive Salmonella Disease Vaccine (6.25 ㎍) Biological: Trivalent Invasive Salmonella Disease Vaccine (12 ㎍) Biological: Trivalent Invasive Salmonella Disease Vaccine (25 ㎍) Biological: Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C) Other: Placebo	University of Maryland, Baltimore	Phase 1
NCT03958045	Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Small Cell Lung Cancer	Combination Product: Rucaparib and Nivolumab	Aman Chauhan University of Kentucky	Phase 2
NCT03955978	TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer	Endometrial Cancer Cancer of the Endometrium	Drug: TSR-042 Radiation: Brachytherapy Procedure: Endometrial biopsy Procedure: Blood draw for immune response	Washington University School of Medicine Tesaro, Inc.	Phase 1
NCT03941730	Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 ESR2 Positive Estrogen Receptor Negative HER2/Neu Negative Metastatic Triple-Negative Breast Carcinoma Progesterone Receptor Negative Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Breast Carcinoma	Biological: Therapeutic Estradiol	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT03935594	Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars	Hypertrophic Scar	Biological: PRP Injection Drug: Saline Injection	Vanderbilt University Medical Center	Phase 2
NCT03920631	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas	B Cell Lymphomas	Drug: Nivolumab Biological: Microtransplantation	Ahmed Galal, MD Duke University	Phase 1
NCT03911388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Neoplasms, Brain Glioblastoma Multiforme Glioblastoma of Cerebellum Neoplasms Astrocytoma Astrocytoma, Cerebellar Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Cerebellar PNET, Childhood Cerebellar Neoplasms Cerebellar Neoplasms, Primary Cerebellar Neoplasm, Malignant Cerebellar Neoplasm Malignant Primary Neoplasm Metastases Neoplasm Malignant Neoplasms, Neuroepithelial Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms, Primary Central Nervous System Neoplasms, Malignant Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Medulloblastoma Recurrent HSV Virus Pediatric Brain Tumor Nervous System Cancer Primitive Neuroectodermal Tumor (PNET) of Cerebellum	Biological: G207	University of Alabama at Birmingham	Phase 1
NCT03899987	Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery	Prostate Adenocarcinoma Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8 Stage IIA Prostate Cancer AJCC v8 Stage IIB Prostate Cancer AJCC v8 Stage IIC Prostate Cancer AJCC v8 Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8	Drug: Aspirin Procedure: Radical Prostatectomy Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) Hemispherx Biopharma	Phase 2
NCT03886493	Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer	Prostate Cancer	Drug: Dupilumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Regeneron Pharmaceuticals	Phase 2
NCT03865082	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)	Solid Tumor	Drug: Tilsotolimod Drug: Nivolumab Drug: Ipilimumab	Idera Pharmaceuticals, Inc. Bristol-Myers Squibb	Phase 2
NCT03864419	Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	Burkitt Lymphoma KSHV-associated Multicentric Castleman Disease Diffuse Large B-Cell Lymphoma	Biological: Rituximab or Rituximab Hyaluronidase Human Drug: Cyclophosphamide Drug: Vincristine Drug: Methotrexate Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Prednisone Drug: Etoposide	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1

해외 바이오의약품 임상 현황 (2019.08.27~2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

NCT03863184	Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL	Mantle Cell Lymphoma	Drug: Acalabrutinib Drug: Lenalidomide Drug: Rituximab	Weill Medical College of Cornell University	Phase 2
NCT03834688	Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age	Mantle Cell Lymphoma	Drug: Venetoclax Drug: Bendamustine Drug: Rituximab	PrECOG, LLC Genentech, Inc.	Phase 2
NCT03829722	Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer	Oropharynx Squamous Cell Carcinoma	Drug: Nivolumab Drug: Carboplatin Drug: Paclitaxel Radiation: Radiation Therapy	University of Michigan Rogel Cancer Center Bristol-Myers Squibb	Phase 2
NCT03810911	Mechanisms of EPO-induced Hypertension	Chronic Kidney Disease Blood Pressure Anemia	Drug: Darbepoetin	VA Office of Research and Development	Phase 2
NCT03768531	Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer	Resectable Biliary Tract Cancer	Drug: Nivolumab Drug: Cabrilizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 2
NCT03735277	Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke	Acute Ischemic Stroke	Biological: HPC, Cord Blood	BHI Therapeutic Sciences	Phase 1
NCT03697564	Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).	Pancreatic Cancer Stage IV	Drug: Gemcitabine Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] Drug: Cabiralizumab	Hitendra Patel Stand Up To Cancer University of California, San Diego	Phase 2
NCT03657576	Trial of C134 in Patients With Recurrent GBM	Glioblastoma Multiforme of Brain Anaplastic Astrocytoma of Brain Gliosarcoma of Brain	Biological: C134	University of Alabama at Birmingham Gateway for Cancer Research National Cancer Institute (NCI)	Phase 1
NCT03634007	Gene Therapy for APOE4 Homozygote of Alzheimer's Disease	Alzheimer Disease Early Onset Alzheimer Disease	Biological: AAVrh.10hPOE2 vector	Weill Medical College of Cornell University	Phase 1
NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCN	Larynx Lip Oral Cancer Digestive Organs--Diseases	Drug: Durvalumab Radiation: Intensity Modulated Radiotherapy Treatments Drug: Tremelimumab	UNC Lineberger Comprehensive Cancer Center AstraZeneca	Phase 1
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Cavernosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT03376477	Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission	Multiple Myeloma	Biological: GM-CSF vaccine Drug: Lenalidomide Drug: Prevnar13 Other: Placebo Prevnar13 Other: Placebo GM-CSF Vaccine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Celgene Aduro Biotech, Inc.	Phase 2
NCT03361852	A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma	Follicular Lymphoma	Drug: Rituximab Biological: Neo Vax	Dana-Farber Cancer Institute	Phase 1
NCT03272633	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	Acute Lymphoblastic Leukemia Acute Myeloid Leukemia in Remission Hematopoietic Cell Transplantation Recipient JAK2 Gene Mutation Loss of Chromosome 17p Mantle Cell Lymphoma Minimal Residual Disease Myelodysplastic Syndrome Non-Hodgkin Lymphoma Plasma Cell Myeloma RAS Family Gene Mutation Recurrent Diffuse Large B-Cell Lymphoma Recurrent Hematologic Malignancy Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Therapy-Related Acute Myeloid Leukemia Therapy-Related Myelodysplastic Syndrome TP53 Gene Mutation	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Irradiated Allogeneic Cells	Rutgers, The State University of New Jersey National Cancer Institute (NCI)	Phase 2
NCT03271229	Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee	Osteo Arthritis Knee	Biological: Concentrated Bone Marrow Aspirate (BMAC) Biological: Platelet-Rich Plasma (PRP)	Mayo Clinic	Phase 2
NCT03259503	Olaparib and High-Dose Chemotherapy in Treating Participants With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	Recurrent Diffuse Large B-Cell Lymphoma Recurrent T-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Hodgkin Lymphoma Refractory T-Cell Non-Hodgkin Lymphoma	Drug: Busulfan Drug: Gemcitabine Drug: Melphalan Drug: Olaparib Procedure: Peripheral Blood Stem Cell Transplantation Other: Pharmacokinetic Study Biological: Rituximab Drug: Vorinostat	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04057365	A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)	Biliary Tract Cancer	Drug: Nivolumab Drug: DKN-01	Massachusetts General Hospital Bristol-Myers Squibb Leap Therapeutics, Inc.	Phase 2
NCT04055623	T-Regulatory Cells in ALS	ALS (Amyotrophic Lateral Sclerosis)	Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections Other: Monthly placebo infusions + 3 times per week placebo injections	The Methodist Hospital System Massachusetts General Hospital The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston North East Amyotrophic Lateral Sclerosis Consortium	Phase 2

해외 바이오의약품 임상 현황 (2019.08.27 ~ 2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

NCT04046549	A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant	Allografts Rejection; Transplant, Kidney Transplant Rejection Kidney Transplantation	Drug: Belatacept Drug: VIB4920	Viola Bio	Phase 2
NCT04009668	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	FSGS MCD Focal Segmental Glomerulosclerosis Minimal Change Disease	Drug: adalimumab	University of Michigan New York University	Phase 2
NCT03982004	Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer	Metastatic Breast Cancer	Device: Epicutaneous cryoimmunotherapy Drug: Topical imiquimod Drug: Pembrolizumab Other: Dermatologic Quality of Life Index Other: Functional Assessment of Cancer Therapy Drug: Intra-lesional GM-CSF Device: Cry-AC	Washington University School of Medicine Merck Sharp & Dohme Corp.	Phase 1
NCT03940950	Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Fraction (SVF) for Treatment of Osteoarthritis of the Knee	Osteo Arthritis Knee Degenerative Joint Disease of Knee	Biological: Autologous Adipose-Derived SVF (Stromal Vascular Fraction) Drug: Placebo	Mayo Clinic	Phase 1
NCT04001413	Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	HPV Positive Oropharyngeal Squamous Cell Carcinoma Oropharynx Cancer HPV-Related Carcinoma	Drug: MEDI0457 Drug: Durvalumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins AstraZeneca	Phase 2
NCT03922477	A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia	Acute Myeloid Leukemia	Drug: Atezolizumab Drug: Hu5F9-G4	Hoffmann-La Roche	Phase 1
NCT03606746	Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants	Kidney Transplant Rejection	Drug: MDR-103	Medeor Therapeutics, Inc.	Phase 2
NCT03996486	Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia	Hemophilia	Drug: BAY1093884	Bayer	Phase 1
NCT04035135	A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)	Guillain-Barré Syndrome	Drug: ANX005 Drug: Intravenous immunoglobulin	Annexon, Inc. ResearchPoint Global International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 1 Phase 2
NCT04035005	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04062708	CHIO3 Trial: Chemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer	Drug: Durvalumab Procedure: Surgery Radiation: Radiotherapy	Alliance Foundation Trials, LLC AstraZeneca	Phase 2
NCT03973918	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG	High Grade Glioma BRAF V600E BRAF V600K Anaplastic Astrocytoma Anaplastic Pleomorphic Xanthoastrocytoma Gliosarcoma Glioblastoma	Drug: Encorafenib Drug: Binimetinib Biological: Research Bloods Biological: Tumor Tissue	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) Array BioPharma	Phase 2
NCT03949855	Belimumab With Rituximab for Primary Membranous Nephropathy	Membranous Nephropathy MN	Drug: Belimumab Drug: Placebo for Belimumab Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) GlaxoSmithKline	Phase 2
NCT04045028	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Multiple Myeloma Non-Hodgkin Lymphoma B-Cell Lymphoma	Drug: Tiragolumab Drug: Daratumumab Drug: Rituximab	Genentech, Inc.	Phase 1

○ 영국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03944876	Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache	Cluster Headache	Drug: Botulinum toxin type A Drug: placebo	Norwegian University of Science and Technology St. Olavs Hospital University College, London Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Catholic University of Valencia University Hospital, Essen	Phase 3
NCT04035005	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3
NCT04035135	A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)	Guillain-Barré Syndrome	Drug: ANX005 Drug: Intravenous immunoglobulin	Annexon, Inc. ResearchPoint Global International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2019.08.27~2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

○ 프랑스 12건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03964792	Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the ̢AS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)	Sickle Cell Disease	Genetic: DREPAGLOBE drug product	Assistance Publique - H̐pitalaux de Paris	Phase 1 Phase 2
NCT03994666	Cell Therapy in Critical Limb Ischemia	Critical Limb Ischemia	Biological: allogeneic umbilical cord-derived mesenchymal stem cells Biological: Placebo (NaCl)	CHU de Reims	Phase 2
NCT03920722	Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis	Microscopic Polyangiitis (MPA)	Drug: Rituximab Drug: placebo	Assistance Publique - H̐pitalaux de Paris French Vasculitis Study Group	Phase 3
NCT03871959	Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	Adenocarcinoma of the Pancreas Adenocarcinoma of the Colon Adenocarcinoma of the Rectum	Drug: Pembrolizumab Drug: DEBIO1143	Centre Leon Berard Merck Sharp & Dohme Corp. Debiopharm International SA	Phase 1
NCT03774901	Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma	Penile Cancer Penile Neoplasms Penile Squamous Cell Carcinoma	Drug: Avelumab	Centre Hospitalier Universitaire de Besancon Pfizer	Phase 2
NCT03726788	Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis	Joint Diseases Knee Therapeutics Magnetic Resonance Imaging	Drug: Botulinum Toxin Type A 100U Drug: Botulinum Toxin Type A 200U Drug: Triamcinolone Hexacetonide Inj Susp 20 MG/ML	Lille Catholic University Allergan	Phase 2
NCT03970954	Low-dose Interleukin-2 in Women With Unexplained Miscarriages	Recurrent Miscarriage	Drug: low-dose IL-2	Assistance Publique - H̐pitalaux de Paris Iltooo Pharma	Phase 1 Phase 2
NCT03946358	Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VoATIL)	Squamous Cell Carcinoma of the Head and Neck Anal Canal Cancer Cervical Cancer	Biological: Blood sample collection Procedure: Tumor biopsies Other: CT scan Drug: Atezolizumab Drug: UCPVax	Centre Hospitalier Universitaire de Besancon Roche Pharma AG National Cancer Institute, France	Phase 2
NCT04042558	A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NSCLC Stage IIIB NSCLC Stage IV EGFR Gene Mutation ALK Gene Rearrangement Positive ROS1 Gene Mutation	Drug: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab Drug: Carboplatin + Pemetrexed + Atezolizumab	Centre Francois Baclesse GFPC	Phase 2
NCT03804359	Personalized Medicine for Membranous Nephropathy	Idiopathic Membranous Nephropathy	Drug: Rituximab	Centre Hospitalier Universitaire de Nice	Phase 2
NCT04035005	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04062656	Perioperative Chemotherapy vs Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG	Gastric Cancer Adenocarcinoma of the Esophagogastric Junction	Drug: Nivolumab Drug: Ipilimumab Drug: relatlimab Drug: Oxaliplatin Drug: Docetaxel Drug: 5-Fluorouracil (5-FU) Drug: Folic acid (FA)	Jan Ellermeier GWT-TUD GmbH University Hospital, Essen	Phase 2
NCT03480334	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy	Classical Hodgkin Lymphoma	Other: Nivolumab plus radiotherapy	University of Cologne	Phase 2
NCT03944876	Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache	Cluster Headache	Drug: Botulinum toxin type A Drug: placebo	Norwegian University of Science and Technology St. Olavs Hospital University College, London Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Catholic University of Valencia University Hospital, Essen	Phase 3
NCT04035005	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

해외 바이오의약품 임상 현황 (2019.08.27~2019.09.02)

한국바이오의약품협회, 2019.9.3
출처: ClinicalTrials.gov

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04004208	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 중국 9건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03941626	Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies	Esophagus Cancer Hepatoma Glioma Gastric Cancer	Biological: CAR-T/TCR-T cells immunotherapy	Shenzhen BinDeBio Ltd. Henan Provincial Hospital	Phase 1 Phase 2
NCT04072900	A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma	Melanoma (Skin)	Drug: Peptide Drug: Anti-PD-1 Drug: rhGM-CSF Drug: Imiquimod 5% Topical Cream	Xiangya Hospital of Central South University	Phase 1
NCT04055792	Sintilimab Combined With Anlotinib in Third Line or Beyond Among Advanced SCLC Patients	Small-cell Lung Cancer	Drug: Sintilimab Drug: Anlotinib	Henan Cancer Hospital	Phase 2
NCT04025957	A Study of SHR-1501 in Patients With Advanced Tumors	Advanced Malignancies	Drug: SHR-1501	Jiangsu HengRui Medicine Co., Ltd.	Phase 1
NCT04008381	Ex-vivo Expanded 款 T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia	Acute Myeloid Leukemia	Biological: Ex-vivo Expanded 款 T Lymphocytes	Wuhan Union Hospital, China Jinan University, China	Phase 1
NCT03521336	Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury	Spinal Cord Injury	Drug: Umbilical Cord Mesenchymal Stem Cells Drug: Placebo	Third Affiliated Hospital, Sun Yat-Sen University West China Hospital Shanghai East Hospital	Phase 2
NCT03521323	Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury	Spinal Cord Injuries	Drug: Umbilical Cord Mesenchymal Stem Cells Drug: Placebos	Third Affiliated Hospital, Sun Yat-Sen University West China Hospital Shanghai East Hospital	Phase 2
NCT03505034	Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury	Spinal Cord Injuries	Drug: Umbilical Cord Mesenchymal Stem Cells	Third Affiliated Hospital, Sun Yat-Sen University West China Hospital Shanghai East Hospital	Phase 2
NCT04073303	BOTOX 款 Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence	Masseter Muscle Prominence	Biological: Botulinum Toxin Type A Other: Placebo	Allergan	Phase 3